Court Halts Boehringer’s COPD Inhaler Comparative Claims Vs. GSK Products

 
• By Brenda Sandburg

GlaxoSmithKline win shows value of going to court as US FDA is less likely to take action against comparative promotions. Court was swayed by GSK survey showing likely harm caused by ‘false and misleading statements not supported by scientific studies.’

Inhaler
Court enjoins Boehringer Ingelheim from making false and misleading statements about GSK's dry powder inhalers

More from Marketing & Advertising

More from Compliance